Partnership as a New Paradigm in China's Pharma Innovation Ecosystem

Over the past decade, the rise of China's Biotech industry and the transformation and upgrading of local enterprises have laid the foundation for the infrastructure and initial exploration of China's pharmaceutical innovation sector. The interplay of international dynamics and economic cycles has led to fluctuations and adjustments in the rules governing pharmaceutical innovation and venture capital investment. China's innovative drug ecosystem is undergoing profound and far-reaching changes, breaking down the self-contained systems of Biotech and Pharma. The new frontier for innovation requires concerted efforts from Biotech, Pharma, capital, and new infrastructure.

Against this backdrop, on October 21, the 2023 Pharmaceutical Innovation Trend Conference · Investment and BD Partnership was held in Suzhou. This conference was hosted by VCBeat and VB100, co-organized by the Qin Mountain Subdistrict Office, Hangzhou Xingcheng Biotechnology Co., Ltd., and CTIC CAPITAL, with support from TandemAI, BFC Group, and Legend Capital.

The conference includes three Mini Forums covering RDC (Radionuclide Drug Conjugates), CGT (Cell and Gene Therapy), BD case studies, and one main forum with four Panel topics. Nearly 200 key participants from the pharmaceutical industry, including Biotech executives, Pharma and MNC strategic BD, state-owned and market-oriented investment institutions, and industrial chain service providers, are invited to attend this event.

Qinshan Subdistrict Office and VCBeat co-hosted the [RDC-Radiopharmaceuticals Mini Forum]The event invited representatives of innovative nuclear medicine projects, industry experts, clinical research experts, investment institutions, and guests from the industrial chain service providers to discuss the latest R&D trends, cutting-edge technologies, and highlights in China's nuclear medicine sector, as well as the deepening relationship between the production, research, and investment in nuclear medicine.

▲RDC-Radiopharmaceuticals Mini Forum Guest Photo

【CGT-Cell and Gene Therapy Mini Forum】 jointly hosted by Hangzhou Xingcheng Biotechnology Co., Ltd. and VCBeat New Medicine，This article delves into the upgrading process of the cell and gene therapy (CGT) industry, aiming to explore the latest development trends in CGT from a CMC perspective. The forum invited representative enterprises in the cell and gene therapy field, CXO companies, innovative enterprises, clinical experts, and investment institutions to deeply discuss current progress, challenges, and future development.

CTIC CAPTIAL and VCBeat jointly host [BD Case Study Mini Forum]The event invites founders and BD heads from pharmaceutical companies, MNCs, and Biotech firms, as well as experts from CROs, legal and regulatory affairs, human resources, and other fields to share and discuss BD cooperation cases. It provides solutions from different perspectives across the entire BD-related value chain, offering practical advice and insights.

▲BD Case Study Mini Forum Guest Photo

The main forum featured four topic-based panels: [Evergreen Investment], [BD Momentum], [AI Advancement], and [New Infrastructure Rationality], exploring investment, BD, AI, and new infrastructure—areas most relevant to pharmaceutical innovation. It presented a thought-provoking and engaging cognitive party from diverse perspectives within a relaxed atmosphere.。

Main Forum Begins: Yu Jing, General Manager of VCBeat's Business Management Center, Delivered a Speech as the Organizer Representative. As a deeply vertical service platform for healthcare industry innovation, VCBeat has been committed to promoting the development of the medical industry and supporting innovative companies in their growth journey. This conference aims to build an integrated communication platform for Biotech, Pharma, capital, and new infrastructure, providing rare connection value for industry peers, and becoming a sincere voice and trendsetter for China’s innovative drug "venture capital" and "BD cooperation."

[Panel 1 - Evergreen Investment]: Wang Xiaoyan, Managing Partner of Jinsha River United Runpu Medical Fund, Dang Feng, Founder of Shishangbai Venture Capital and Qinghao Medical Management Consulting, Chen Wei, Investment Director of Sichuan Development Hongke Equity Investment, and Ji Qianqian, Senior Investment Manager of Shenzhen HTI Group Co., Ltd., under the moderation of Mu Lei, Senior Researcher of VCBeat, discussed"Rich but Busy: Where is the Trend for GPs and State-owned Capital Watching Projects?"Launch the discussion.

▲Panel1-Evergreen Investment

[Panel 2-BD Momentum]: Lu Qiwen, Director of BFC Group; Huang Li, Director of Investment and Mergers & Acquisitions at Jin Sai Pharmaceutical; Jiang Dawei, Director of Business Development at the Global R&D Collaboration Department of Shanghai Pharmaceutical Group; Qiu Wenxiong, Partner at Zhong Lun Law Firm's Shanghai Office; and Gao Yunan, Managing Director of BFC Group"Where Are Innovative Drug Companies Headed: License In or Out? Riding the BD Wave to Navigate Cycles"Expand the sharing.

▲Panel2-BD Momentum

[Panel 3 - AI Scaling]: How to integrate and connect key elements of the industrial chain such as capital, innovation and R&D, and clinical aspects? Amidst a surging tide of rapid changes.What kind of ecosystem partners do AI + new drug developers need?TandemAI's Vice President of Software Engineering, Li Huilin, Evopoint Biosciences' Chief Technology Officer, Hu Yonghan, Space Peptides' CEO, He Runze, DeepStone Biologics' BD Director, Yang Wenshan, and FIL Capital Management (Hong Kong) Limited's Senior Investment Manager, Wang Bo, discussed this topic.

▲Panel3-AI Ramp-Up

[Panel 4 - Rationality of New Infrastructure]: Under the professional and humorous "fault-finding" style moderation of Liu Xiao, Business Vice President of Hangzhou Xingcheng Biotechnology Co., Ltd., Wang Lijun, Co-founder and CEO of Hangzhou Xingcheng Biotechnology Co., Ltd., Xu Rong, Co-founder and Technical Vice President of Beijing T&L Biotechnology Co., Ltd., Hua Liqiang, Global Vice President and General Manager of China for Repligen, Zou Yang, R&D Vice President of LePure, and Xu Chong, Director of Key Account Sales at Danaher Life Science Platform, discussed starting from CMC."The Future Path of Cooperation Between Local and Overseas Enterprises"Launch a discussion on how to rationally understand "China-produced alternatives."

▲Panel4-New Infrastructure Rationality

Thus, the "2023 Pharmaceutical Innovation Trend Conference · Investment and BD Partnership" has successfully concluded. Breakthroughs in the pharmaceutical innovation industry require the cooperation of all parties to solve problems. As Li Datao, founder of VCBeat, said, the solution to a problem often lies outside the problem itself—finding a new perspective is key. We also look forward to experts in the field of pharmaceutical innovation leading their teams to create new stories in China.

▲Wonderful Moments